Pacira BioSciences, Inc. (PCRX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Pacira BioSciences, Inc. reported revenue of $726.41M, up 3.6% from the prior year. The company was profitable, with a net margin of 1.0%. It held $1.26B in total assets against $571.81M in total liabilities.
Key ratios (FY2025)
2.6%
Operating margin
1.0%
Net margin
1.0%
Return on equity
+3.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $726.41M | $700.97M | $674.98M | $666.82M | $541.53M | $429.65M | $418.93M | $332.43M | $284.34M | $270.07M |
| Cost of Revenue | $149.75M | $170.43M | $184.67M | $199.29M | $140.25M | $117.33M | $106.71M | $86.84M | $87.92M | $110.10M |
| Operating Income | $19.19M | -$73.37M | $87.67M | $60.02M | $89.92M | $46.35M | $10.48M | $15.91M | -$24.94M | -$32.02M |
| Net Income | $7.03M | -$99.56M | $41.95M | $15.91M | $41.98M | $145.52M | -$11.02M | -$471.0K | -$42.61M | -$37.95M |
| EPS (Diluted) | $0.16 | $-2.15 | $0.89 | $0.34 | $0.92 | $3.33 | $-0.27 | $-0.01 | $-1.07 | $-1.02 |
| Total Assets | $1.26B | $1.55B | $1.57B | $1.68B | $2.08B | $1.27B | $831.07M | $689.35M | $628.37M | $391.47M |
| Total Liabilities | $571.81M | $775.17M | $704.26M | $906.19M | $1.34B | $654.83M | $476.12M | $368.13M | $348.89M | $172.49M |
| Shareholders' Equity | $693.11M | $778.35M | $870.13M | $775.01M | $730.41M | $619.69M | $354.94M | $321.23M | $279.48M | $218.98M |
| Cash & Equivalents | $158.54M | $276.77M | $153.30M | $104.14M | $585.58M | $99.96M | $78.23M | $132.53M | $54.13M | $35.94M |
| Operating Cash Flow | $151.99M | $189.39M | $154.65M | $145.27M | $125.72M | $77.03M | $70.52M | $48.87M | $17.79M | — |
| Capital Expenditures | $15.33M | $10.64M | $15.16M | $30.08M | $45.87M | $37.80M | $10.16M | $14.51M | $19.27M | $24.71M |
| Shares Outstanding | 41.12M | 46.24M | 46.48M | 45.93M | 44.73M | 43.64M | 41.91M | 41.22M | 40.67M | 37.48M |